Our trials hello 2019-04-12T17:12:36+12:00

Our trials …

As with all things in life you need ‘the proof of the pudding!’ to judge things. So here are some of the trials we have facilitated in the past and those we are currently engaged on……


A multi-centre randomised controlled trial to determine if 7 days of intravenous β-lactam in combination with standard therapy will lead to better complication-free survival 90-days after randomisation, compared to standard therapy alone in patients with MRSA blood stream infection.

HEAT Trial

A phase 2b randomised controlled trial investigating the safety and efficacy of intravenous paracetamol versus placebo (5% dextrose) in the treatment of fever in critically ill patients with known or suspected infection.


A multi-centre, randomised, single blinded clinical trial comparing standard vs. conservative oxygen therapy in mechanically ventilated adults in the Intensive Care Unit.


A 52- week, open label, parallel group, multi-centre, phase III, randomised controlled trial to compare the efficacy and safety of three asthma treatment regimens. Recruitment in New Zealand, Australia, Italy and the United Kingdom.


A 8,000 patient, multi-centre, randomised controlled trial to compare the safety and efficacy of Plasma-Lyte 148® in comparison with saline .


A 52- week, open label, parallel group, multi-centre, phase III, randomised controlled trial to compare the efficacy and safety of two asthma treatment regimens. Recruitment in New Zealand only.


A multi-centre, phase II, randomised, open label, clinical trial comparing combined prophylactic intravenous paracetamol and early targeted physical cooling for fever with standard temperature management in mechanically ventilated adults without acute brain pathologies who are expected to be ventilated beyond the day after randomisation.


A randomised, embedded, multi-factorial, adaptive platform clinical trial. The Trial will simultaneously investigate the best of two or three options in 4 areas of practice for patients admitted to intensive care with pneumonia. Patients will be randomly allocated to one of the options in each of these four areas.


A novel, multi-centred cluster randomised double cross over feasibility trial
investigating the effect of using 0.9% saline or Plasma Lyte® 148 as fluid therapy in intensive care patients on the risk of developing acute kidney injury.

Supp PN Trial

A stratified, prospective, multi-centre, unblinded, randomised, parallel-group phase II study to determine whether a supplemental parenteral nutrition strategy will reliably and safely increase energy intake when compared to usual care.


The TAME trial is a phase III, multi-centre, randomised, parallel-group, clinical trial in resuscitated cardiac arrest patients admitted to the intensive care unit to determine whether targeted therapeutic mild hypercapnia (TTMH) improves neurological outcome at 6 months compared to standard care (targeted normocapnia) (TN).


A 4,000 patient, multi-centre, double-blinded, randomised, controlled, parallel-group, phase III clinical trial to determine if augmentation of calorie delivery using energy dense enteral nutrition in mechanically ventilated patients improves 90 day survival when compared to routine care.


The TASI Study will test the potential overall benefit of the TightRope versus syndesmotic screw fixation for ankle injuries.


The TTM2 trial is investigating whether targeted temperature management (TTM) to 33°C improves survival and neurological outcome at 6 months compared to a strategy of targeting normothermia and avoiding fever above 37.7°C.